MedTrace Logo

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

NCT00770003 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2015-08-14

No results posted yet for this study

Summary

The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

AZD8848

nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month

DRUG

Placebo

nasal spray solution. Once weekly intranasal administrations for one month.

Sponsors & Collaborators

Principal Investigators

  • Lennart Greiff, MD PhD · Lund University Hospital

  • Leif T Eriksson, MD, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-03-31
Completion
2010-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770003 on ClinicalTrials.gov